Latest Breaking News On - Nicolas fellmann - Page 21 : comparemela.com

Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe - Biophytis (NASDAQ:BPTS)

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA ((Nasdaq CM:BPTS, PARIS:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics

United kingdomUnited statesFrance generalNicolas fellmannNizar berradaAntoine denryEuropean medicine agencyDrug administrationExchange commissionEthics committeeChief executive officerEmergency use authorizationDuchenne muscular dystrophyEuronext growthAmerican depositary sharesNasdaq capital market

Biophytis has Requested a Pre-Submission Meeting with the FDA for an

Biophytis has Requested a Pre-Submission Meeting with the FDA for an .

United statesUnited kingdomFrance generalAntoine denryNizar berradaAgathe boggioNicolas fellmannEuropean medicine agencyDrug administrationExchange commissionNews networkEuronext growth parisEmergency use authorizationChief executive officerAcute respiratory distress syndromeEmergency use application

Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomNicolas fellmannAntoine denryNizar berradaAgathe boggioEuropean medicine agencyDrug administrationExchange commissionEuronext growth parisEmergency use authorizationChief executive officerAcute respiratory distress syndromeEmergency use applicationDuchenne muscular dystrophy

Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos for the Treatment of COVID-19

Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos for the Treatment of COVID-19
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomNicolas fellmannNizar berradaAgathe boggioAntoine denryEuropean medicine agencyDrug administrationExchange commissionEuronext growth parisEmergency use authorizationChief executive officerAcute respiratory distress syndromeEmergency use applicationDuchenne muscular dystrophy

Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19 - Biophytis (NASDAQ:BPTS)

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 20, 2023 / Biophytis SA (Nasdaq CM:BPTS)(PARIS:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics

United statesFrance generalUnited kingdomAntoine denryAgathe boggioNizar berradaNicolas fellmannExchange commissionDrug administrationEuropean medicine agencyEmergency use authorizationChief executive officerAcute respiratory distress syndromeEmergency use applicationDuchenne muscular dystrophyEuronext growth